Student or educator? Sign up with your school email and get 6 months of Pro free.
Cited by 115

The DOI matches its Crossref record; 1 of the 1 references it cites were found in a registry or an index.

Oligomerization and Membrane-binding Properties of Covalent Adducts Formed by the Interaction of α-Synuclein with the Toxic Dopamine Metabolite 3,4-Dihydroxyphenylacetaldehyde (DOPAL)

Follmer, Cristian, Coelho-Cerqueira, Eduardo, Yatabe-Franco, Danilo Y., Araujo, Gabriel D.T., Pinheiro, Anderson S., Domont, Gilberto B., Eliezer, David·2015·Journal of Biological Chemistry

Overview

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1074/jbc.m115.686584

Cites

1 of 1 references verified0 citation errors · 0 not checkable

Statistics

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Show all 1 references

Research works printed but not linked: 61

  1. Langston, 2006, The Parkinson's complex: parkinsonism is just the tip of the iceberg, Ann. Neurol, 59, 591, 10.1002/ana.20834 · DOI · Paper page
  2. Langston, 1983, Chronic parkinsonism in humans due to a product of meperidine-analog synthesis, Science, 219, 979, 10.1126/science.6823561 · DOI · Paper page
  3. Sulzer, 2007, Multiple hit hypotheses for dopamine neuron loss in Parkinson's disease, Trends Neurosci, 30, 244, 10.1016/j.tins.2007.03.009 · DOI · Paper page
  4. Spillantini, 1997, α-Synuclein in Lewy bodies, Nature, 388, 839, 10.1038/42166 · DOI · Paper page
  5. Spillantini, 1998, α-Synuclein in filamentous inclusions of Lewy bodies from Parkinson's disease and dementia with Lewy bodies, Proc. Natl. Acad. Sci. U.S.A, 95, 6469, 10.1073/pnas.95.11.6469 · DOI · Paper page
  6. Polymeropoulos, 1997, Mutation in the α-synuclein gene identified in families with Parkinson's disease, Science, 276, 2045, 10.1126/science.276.5321.2045 · DOI · Paper page
  7. Xu, 2002, Dopamine-dependent neurotoxicity of α-synuclein: a mechanism for selective neurodegeneration in Parkinson disease, Nat. Med, 8, 600, 10.1038/nm0602-600 · DOI · Paper page
  8. Hasegawa, 2006, α-Synuclein facilitates the toxicity of oxidized catechol metabolites: implications for selective neurodegeneration in Parkinson's disease, FEBS Lett, 580, 2147, 10.1016/j.febslet.2006.03.018 · DOI
  9. Filloux, 1993, Pre- and postsynaptic neurotoxic effects of dopamine demonstrated by intrastriatal injection, Exp. Neurol, 119, 79, 10.1006/exnr.1993.1008 · DOI · Paper page
  10. Follmer, 2014, Monoamine oxidase and α-synuclein as targets in Parkinson's disease therapy, Exp. Rev. Neurother, 14, 703, 10.1586/14737175.2014.920235 · DOI
  11. Burke, 2003, 3,4-Dihydroxyphenylacetaldehyde is the toxic dopamine metabolite in vivo: implications for Parkinson's disease pathogenesis, Brain Res, 989, 205, 10.1016/S0006-8993(03)03354-7 · DOI · Paper page
  12. Goldstein, 2011, Catechols in post-mortem brain of patients with Parkinson disease, Eur. J. Neurol, 18, 703, 10.1111/j.1468-1331.2010.03246.x · DOI
  13. Goldstein, 2013, Determinants of buildup of the toxic dopamine metabolite DOPAL in Parkinson's disease, J. Neurochem, 126, 591, 10.1111/jnc.12345 · DOI · Paper page
  14. Fitzmaurice, 2013, Aldehyde dehydrogenase inhibition as a pathogenic mechanism in Parkinson disease, Proc. Natl. Acad. Sci. U.S.A, 110, 636, 10.1073/pnas.1220399110 · DOI · Paper page
  15. Burke, 2008, Aggregation of α-synuclein by DOPAL, the monoamine oxidase metabolite of dopamine, Acta Neuropathol, 115, 193, 10.1007/s00401-007-0303-9 · DOI · Paper page
  16. Coelho-Cerqueira, 2013, α-Synuclein as an intrinsically disordered monomer–fact or artefact?, FEBS J, 280, 4915, 10.1111/febs.12471 · DOI
  17. Anderson, 2011, Oxidation of 3,4-dihydroxyphenylacetaldehyde, a toxic dopaminergic metabolite, to a semiquinone radical and an ortho-quinone, J. Biol. Chem, 286, 26978, 10.1074/jbc.M111.249532 · DOI
  18. Abramoff, 2004, Image processing with ImageJ, Biophot. Int, 11, 36
  19. Delaglio, 1995, NMRPipe: a multidimensional spectral processing system based on UNIX pipes, J. Biomol. NMR, 6, 277, 10.1007/BF00197809 · DOI · Paper page
  20. Bermel, 2006, Protonless NMR experiments for sequence-specific assignment of backbone nuclei in unfolded proteins, J. Am. Chem. Soc, 128, 3918, 10.1021/ja0582206 · DOI · Paper page
  21. Chandra, 2003, A broken α-helix in folded α-synuclein, J. Biol. Chem, 278, 15313, 10.1074/jbc.M213128200 · DOI · Paper page
  22. Eliezer, 2001, Conformational properties of α-synuclein in its free and lipid-associated states, J. Mol. Biol, 307, 1061, 10.1006/jmbi.2001.4538 · DOI · Paper page
  23. Eliezer, 2012, Distance information for disordered proteins from NMR and ESR measurements using paramagnetic spin labels, Methods Mol. Biol, 895, 127, 10.1007/978-1-61779-927-3_10 · doi:10.1007/978-1-61779-927-3_10
  24. Shvadchak, 2011, Specificity and kinetics of α-synuclein binding to model membranes determined with fluorescent excited state intramolecular proton transfer (ESIPT) probe, J. Biol. Chem, 286, 13023, 10.1074/jbc.M110.204776 · DOI
  25. Ysselstein, 2015, Effects of impaired membrane interactions on α-synuclein aggregation and neurotoxicity, Neurobiol. Dis, 79, 150, 10.1016/j.nbd.2015.04.007 · DOI
  26. Scholtz, 1991, Parameters of helix-coil transition theory for alanine-based peptides of varying chain lengths in water, Biopolymers, 31, 1463, 10.1002/bip.360311304 · DOI · Paper page
  27. Shvadchak, 2011, The mode of α-synuclein binding to membranes depends on lipid composition and lipid to protein ratio, FEBS Lett, 585, 3513, 10.1016/j.febslet.2011.10.006 · DOI
  28. Guang, 2006, High-throughput screening for monoamine oxidase-A and monoamine oxidase-B inhibitors using one-step fluorescence assay, Acta Pharmacol. Sin, 27, 760, 10.1111/j.1745-7254.2006.00336.x · DOI
  29. Dixon, 1968, Reversible blocking of free amines with citraconic anhydride, Biochem. J, 109, 312, 10.1042/bj1090312 · doi:10.1042/bj1090312
  30. Follmer, 2007, Dopamine affects the stability, hydration and packing of protofibrils and fibrils of wild-type and variants of α-synuclein, Biochemistry, 46, 472, 10.1021/bi061871+ · DOI
  31. Coelho-Cerqueira, 2014, Pitfalls associated with the use of thioflavin-T to monitor anti-fibrillogenic activity, Bioorg. Med. Chem. Lett, 24, 3194, 10.1016/j.bmcl.2014.04.072 · DOI
  32. Yagi, 2005, Amyloid fibril formation of α-synuclein is accelerated by preformed amyloid seeds of other proteins: implications for the mechanism of transmissible conformational diseases, J. Biol. Chem, 280, 38609, 10.1074/jbc.M508623200 · DOI
  33. Leong, 2009, Formation of dopamine-mediated α-synuclein-soluble oligomers requires methionine oxidation, Free Radic. Biol. Med, 46, 1328, 10.1016/j.freeradbiomed.2009.02.009 · DOI
  34. Zhou, 2010, Met residues oxidation stabilizes non-toxic oligomers of α-synuclein through strengthening the auto-inhibitory intra-molecular long-range interactions, Biochim. Biophys. Acta, 1802, 322, 10.1016/j.bbadis.2009.12.004 · DOI
  35. Carmo-Gonçalves, 2014, UV-induced selective oxidation of Met-5 to Met-sulfoxide leads to the formation of neurotoxic fibril-incompetent α-synuclein oligomers, Amyloid, 21, 163, 10.3109/13506129.2014.912208 · DOI
  36. Rauniyar, 2009, Detection and identification of 4-hydroxy-2-nonenal Schiff-base adducts along with products of Michael addition using data-dependent neutral loss-driven MS3 acquisition: method evaluation through an in vitro study on cytochrome c oxidase modifications, Proteomics, 9, 5188, 10.1002/pmic.200900116 · DOI
  37. Li, 2005, Inhibition of α-synuclein fibrillization by dopamine analogs via reaction with the amino group of α-synuclein. Implication for dopaminergic neurodegeneration, FEBS J, 272, 3661, 10.1111/j.1742-4658.2005.04792.x · DOI
  38. Lin, 2005, 4-Oxo-2-nonenal is both more neurotoxic and more protein reactive than 4-hydroxy-2-nonenal, Chem. Res. Toxicol, 18, 1219, 10.1021/tx050080q · DOI · Paper page
  39. Sung, 2007, Residual structure, backbone dynamics, and interactions within the synuclein family, J. Mol. Biol, 372, 689, 10.1016/j.jmb.2007.07.008 · DOI
  40. Kjaergaard, 2011, Sequence correction of random coil chemical shifts: correlation between neighbor correction factors and changes in the Ramachandran distribution, J. Biomol. NMR, 50, 157, 10.1007/s10858-011-9508-2 · DOI · Paper page
  41. Kjaergaard, 2011, Random coil chemical shifts for intrinsically disordered proteins: effects of temperature and pH, J. Biomol. NMR, 49, 139, 10.1007/s10858-011-9472-x · DOI · Paper page
  42. Lotharius, 2002, Pathogenesis of Parkinson's disease: dopamine, vesicles and α-synuclein, Nat. Rev. Neurosci, 3, 932, 10.1038/nrn983 · DOI · Paper page
  43. Fowler, 1997, Age-related increases in brain MAO B in healthy human subjects, Neurobiol. Aging, 18, 431, 10.1016/S0197-4580(97)00037-7 · DOI · Paper page
  44. Lamensdorf, 2000, Metabolic stress in PC12 cells induces the formation of the endogenous dopaminergic neurotoxin, 3,4-dihydroxyphenylacetaldehyde, J. Neurosci. Res, 60, 552, 10.1002/(SICI)1097-4547(20000515)60:4<552::AID-JNR14>3.0.CO;2-U · DOI
  45. Mizuno, 1989, Deficiencies in complex I subunits of the respiratory chain in Parkinson's disease, Biochem. Biophys. Res. Commun, 163, 1450, 10.1016/0006-291X(89)91141-8 · DOI · Paper page
  46. Conway, 2001, Kinetic stabilization of the α-synuclein protofibril by a dopamine-α-synuclein adduct, Science, 294, 1346, 10.1126/science.1063522 · DOI · Paper page
  47. Bisaglia, 2010, Dopamine quinones interact with α-synuclein to form unstructured adducts, Biochem. Biophys. Res. Commun, 394, 424, 10.1016/j.bbrc.2010.03.044 · DOI
  48. Qin, 2007, Effect of 4-hydroxy-2-nonenal modification on α-synuclein aggregation, J. Biol. Chem, 282, 5862, 10.1074/jbc.M608126200 · DOI · Paper page
  49. Rees, 2009, Protein reactivity of 3,4-dihydroxyphenylacetaldehyde, a toxic dopamine metabolite, is dependent on both the aldehyde and catechol, Chem. Res. Toxicol, 22, 1256, 10.1021/tx9000557 · DOI
  50. Umanah, 2009, Cross-linking of a DOPA-containing peptide ligand into its G protein-coupled receptor, Biochemistry, 48, 2033, 10.1021/bi802061z · doi:10.1021/bi802061z
  51. Yu, 1999, Role of l-3, 4-dihydroxyphenylalanine in mussel adhesive proteins, J. Am. Chem. Soc, 121, 5825, 10.1021/ja990469y · DOI · Paper page
  52. Georgieva, 2008, Membrane-bound α-synuclein forms an extended helix: long-distance pulsed ESR measurements using vesicles, bicelles, and rodlike micelles, J. Am. Chem. Soc, 130, 12856, 10.1021/ja804517m · DOI · Paper page
  53. Bussell, 2003, structural and functional role for 11-mer repeats in α-synuclein and other exchangeable lipid binding proteins, J. Mol. Biol, 329, 763, 10.1016/S0022-2836(03)00520-5 · DOI · Paper page
  54. Ulmer, 2005, Structure and dynamics of micelle-bound human α-synuclein, J. Biol. Chem, 280, 9595, 10.1074/jbc.M411805200 · DOI · Paper page
  55. Snead, 2014, α-Synuclein function and dysfunction on cellular membranes, Exp. Neurobiol, 23, 292, 10.5607/en.2014.23.4.292 · DOI · Paper page
  56. Burré, 2012, Systematic mutagenesis of α-synuclein reveals distinct sequence requirements for physiological and pathological activities, J. Neurosci, 32, 15227, 10.1523/JNEUROSCI.3545-12.2012 · DOI · Paper page
  57. Maltsev, 2013, Site-specific interaction between α-synuclein and membranes probed by NMR-observed methionine oxidation rates, J. Am. Chem. Soc, 135, 2943, 10.1021/ja312415q · DOI
  58. Zarbiv, 2014, Lysine residues at the first and second KTKEGV repeats mediate α-synuclein binding to membrane phospholipids, Neurobiol. Dis, 70, 90, 10.1016/j.nbd.2014.05.031 · DOI
  59. Bussell, 2004, Effects of Parkinson's disease-linked mutations on the structure of lipid-associated α-synuclein, Biochemistry, 43, 4810, 10.1021/bi036135+ · DOI
  60. Fares, 2014, The novel Parkinson's disease linked mutation G51D attenuates in vitro aggregation and membrane binding of α-synuclein, and enhances its secretion and nuclear localization in cells, Hum. Mol. Genet, 23, 4491, 10.1093/hmg/ddu165 · DOI · Paper page
  61. Bartels, 2014, N-α-Acetylation of α-synuclein increases its helical folding propensity, GM1 binding specificity and resistance to aggregation, PLoS One, 9, e103727, 10.1371/journal.pone.0103727 · DOI · Paper page

Cited by

See all 115

Metadata

Authors
Follmer, C., Coelho-Cerqueira, E., Yatabe-Franco, D. Y., Araujo, G. D. T., Pinheiro, A. S., Domont, G. B., & Eliezer, D.
Venue
Journal of Biological Chemistry
Publisher
Elsevier BV
Published
2015-11
Volume
290
Issue
46
Pages
27660-27679
ISSN
0021-9258
Cited by
115
References
1
Language
en
Licence
Funders
  • Fundação Carlos Chagas Filho de Amparo à Pesquisa do Estado do Rio de Janeiro
  • Conselho Nacional de Desenvolvimento Científico e Tecnológico
  • National Institutes of Health (R37AG019391)

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: Oligomerization and Membrane-binding Properties of Covalent Adducts Formed by the Interaction of α-Synuclein with the Toxic Dopamine Metabolite 3,4-Dihydroxyphenylacetaldehyde (DOPAL). https://app.cochat.ai/papers/10.1074/jbc.m115.686584
The paper
Follmer, C., Coelho-Cerqueira, E., Yatabe-Franco, D. Y., Araujo, G. D. T., Pinheiro, A. S., Domont, G. B., & Eliezer, D. (2015). Oligomerization and Membrane-binding Properties of Covalent Adducts Formed by the Interaction of α-Synuclein with the Toxic Dopamine Metabolite 3,4-Dihydroxyphenylacetaldehyde (DOPAL). Journal of Biological Chemistry. https://doi.org/10.1074/jbc.m115.686584

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.